Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 357Unspecified Adult Solid Tumor, Protocol Specific 302Advanced Solid Tumor 274Solid Tumor 237Solid Tumors 233Mesothelioma 84Mesothelioma, Malignant 79Solid Tumor, Adult 65Carcinoma, Non-Small-Cell Lung 57Ovarian Neoplasms 38Melanoma 35Lung Neoplasms 29Advanced or Metastatic Solid Tumors 27Neoplasms 26Carcinoma, Renal Cell 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Pancreatic Neoplasms 25Solid Tumours 24Sarcoma 24Colorectal Neoplasms 24Retinoblastoma 22Esophageal Neoplasms 22Advanced Malignant Solid Tumors 22Unspecified Childhood Solid Tumor, Protocol Specific 21Squamous Cell Carcinoma of Head and Neck 20Breast Neoplasms 20Advanced Solid Tumours 20Triple Negative Breast Neoplasms 19Small Cell Lung Carcinoma 19

Interventions

atezolizumab 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Treatment-Refractory Solid Tumors × Other solid neoplasm × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡